

Jubilant Biosys (BVI) Ltd
Balance Sheet

As at 31st Mar	Notes No	2015	2015	2014	2014
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	1,397,501	69,846	1,397,501	69,846
Reserves & surplus	2	(27,134)	15,801	(22,877)	12,507
		1,370,367	85,648	1,374,624	82,354
Current liabilities					
Trade payables	3	2,826	177	1,280	77
		2,826	177	1,280	77
Total		1,373,193	85,825	1,375,904	82,430
II. ASSETS					
Non-current investments	4	1,371,501	85,719	1,371,501	82,167
		1,371,501	85,719	1,371,501	82,167
Current assets					
Cash & bank balances	5	1,371	86	4,174	250
Short-term loans and advances	6	321	20	229	14
		1,692	106	4,403	264
Total		1,373,193	85,825	1,375,904	82,430

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT BIOSYS (BVI) LTD
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2015	2015	2014	2014
Particulars		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	7	4,257	261	4,527	274
Total expenses		4,257	261	4,527	274
Profit for the Year		(4,257)	(261)	(4,527)	(274)

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT BIOSYS (BVI) LIMITED

CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(4,257)	(261)	(4,527)	(274)
Operating profit before working capital changes	(4,257)	(261)	(4,527)	(274)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	(92)	(6)	(3)	(0)
Increase/(Decrease) in trade and other payables	1,546	95	701	42
Net cash inflow/(outflow) in course of operating activities	(2,803)	(172)	(3,829)	(232)
B. Cash flow arising from investing activities :				
(Purchase)/sale of investments (net)(Including in Subsidiaries)	-	-	(15,000)	(906)
Net cash inflow/(outflow) in course of investing activities	-	-	(15,000)	(906)
C. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	-	-	20,000	1,208
Net cash inflow/(outflow) in course of financing activities	-	-	20,000	1,208
D. Foreign currency translation difference arising on consolidation				
		8		17
Net Increase in cash & cash equivalents (A+B+C+D)	(2,803)	(164)	1,170	87
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	4,174	250	3,004	163
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	1,371	86	4,174	250

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

Jubilant Biosys (BVI) Ltd
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
10,000,000 equity shares of USD 1 each	-	-	-	-
Preference share capital	-	-	-	-
(Previous Year 10,000,000 equity shares of USD 1 each)	-	-	-	-
Issued & Subscribed				
1,397,501 equity shares of USD 1 each	-	-	-	-
Preference share capital	-	-	-	-
(Previous Year 1,397,501 equity shares of USD 1 each)	-	-	-	-
Paid up				
1,397,501 equity shares of USD 1 each	1,397,501	69,846.49	1,397,501	69,846
(Previous Year 1,397,501 equity shares of USD 1 each)	-	-	-	-
Add: equity shares forfeited (paid up)	-	-	-	-
	1,397,501.00	69,846.49	1,397,501	69,846

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares in the company

As at 31st March	2015	2015	2014	2014
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	1,397,501	100.00%	1,397,501	100.00%

4) The reconciliation of the number of shares outstanding as at beginning and at the end of reporting period

As at 31st March	2015	2015	2014	2014
Name of the shareholder	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Numbers of shares at the beginning	1,397,501.00	69,846	1,377,501.00	68,772
Add: Shares issued during the year	-	-	20,000.00	1,074
Numbers of shares at the end	1,397,501	69,846	1,397,501	69,846

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st March	2015	2015	2014	2014
Particulars	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company	1,397,501	69,846.49	1,397,501	69,846
1,397,501 equity shares of USD 1 each				

Jubilant Biosys (BVI) Ltd
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	13,673.54	-	-
Foreign Currency Translation Reserve During the Year	-	3,555.15	-	13,673.54
	-	17,228.70	-	13,673.54
Surplus as per P&L Account				
As per last Balance Sheet	(22,877)	(1,166)	(18,350)	(892)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(4,257)	(261)	(4,527)	(274)
	(27,134)	(1,427)	(22,877)	(1,166)
	(27,134)	15,801	(22,877)	12,507
3. TRADE PAYABLES				
Trade payables-others	2,826	177	1,280	77
	2,826	177	1,280	77
4. NON CURRENT INVESTMENTS				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Biosys (Singapore) Pte Ltd	1,371,501	85,719	1,371,501	82,167
1371501 shares of USD 1 each	1,371,501	85,719	1,371,501	82,167
5. CASH AND BANK BALANCES				
Balances with banks:				
- On current accounts	1,371	86	4,174	250
	1,371	86	4,174	250
6. SHORT TERM LOANS AND ADVANCES				
- Prepaid Expenses	321	20	229	14
	321	20	229	14
7. OTHER EXPENSE				
Legal , professional & consultancy charges	4,237	260	4,427	268
Bank Charges	20	1	100	6
	4,257	261	4,527	274